Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NTGN

Neon Therapeutics (NTGN) Stock Price, News & Analysis

Neon Therapeutics logo

About Neon Therapeutics Stock (NASDAQ:NTGN)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$3.07
$3.07
50-Day Range
$2.77
$3.07
52-Week Range
$0.88
$6.25
Volume
N/A
Average Volume
516,108 shs
Market Capitalization
$88.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Remove Ads
Receive NTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NTGN Stock News Headlines

BCYC Bicycle Therapeutics plc
NTGN_old Historical Data
Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
NBCO Neon Bloom, Inc.
See More Headlines

NTGN Stock Analysis - Frequently Asked Questions

Neon Therapeutics Inc (NASDAQ:NTGN) released its quarterly earnings data on Monday, March, 2nd. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.03.

Neon Therapeutics (NTGN) raised $101 million in an initial public offering (IPO) on Wednesday, June 27th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities served as the underwriters for the IPO and Oppenheimer was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neon Therapeutics investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Sorrento Therapeutics (SRNE), Aduro Biotech (ADRO) and Altimmune (ALT).

Company Calendar

Last Earnings
3/02/2020
Today
4/04/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:NTGN
CIK
N/A
Fax
N/A
Employees
102
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-79,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.50 per share
Price / Book
6.14

Miscellaneous

Free Float
N/A
Market Cap
$88.93 million
Optionable
Not Optionable
Beta
-0.81
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:NTGN) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners